Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alan Block

Podiatrist Florence, SC Doctor of Podiatric Medicine

NPI 1427013093 CMS profile 246395

230 Cherokee Rd, Florence, SC 29501

Open in the dashboard

General payments

$96,207

334 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alan Block of Florence, SC is reported in the CMS Open Payments database as having received $96,207 across 334 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $372 4
2024 General $6,976 38
2023 General $4,456 20
2022 General $26,146 40
2021 General $10,903 59
2020 General $4,036 45
2019 General $43,320 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Block
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Alan Block were reported at $372. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Alan Block Podiatrist median Middle half National median
2019 $43,320 $196 $72–$601 $163
2020 $4,036 $118 $38–$335 $114
2021 $10,903 $169 $57–$573 $132
2022 $26,146 $220 $74–$782 $149
2023 $4,456 $208 $71–$635 $160
2024 $6,976 $237 $87–$681 $164
2025 $372 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. TissueTech, Inc. $32,361 30 payments
  2. Amniox Medical, Inc. $18,855 18 payments
  3. Cook Incorporated $13,009 12 payments
  4. Cook Medical LLC $8,735 41 payments
  5. Geistlich Pharma, North America, Inc. $6,736 17 payments
  6. Medtronic Vascular, Inc. $2,973 6 payments
  7. Extremity Medical $2,357 8 payments
  8. Stryker Corporation $1,981 17 payments
  9. Heron Therapeutics, Inc. $1,533 3 payments
  10. Medtronic, Inc. $1,147 2 payments
  11. Other $6,520 180 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $34,645 16 payments
  2. Travel and Lodging $25,713 53 payments
  3. Food and Beverage $12,184 252 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $12,000 7 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,490 4 payments
  6. Honoraria $3,175 2 payments
Products named General payments · program years 2019–2025
  1. NEOX Human Tissue Products $18,855 18 payments
  2. CLARIX Human Tissue Products $18,855 18 payments
  3. NEOX Human Tissue Products $9,652 16 payments
  4. CLARIX Human Tissue Products $9,652 16 payments
  5. Cook Medical Zilver PTX $7,964 18 payments
  6. Cook Medical IAA $6,807 7 payments
  7. Cook Medical Accessories $5,519 16 payments
  8. Derma-Gide $5,311 1 payment
  9. VenaSeal $2,899 4 payments
  10. Zynrelef $1,533 3 payments
  11. Other $15,573 274 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

50

Median for Podiatry: 160

Drug cost

$679

Median for Podiatry: $2,368

Branded share of claims

26%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gentamicin Sulfate Generic 16 $554
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $63
Cephalexin Generic 21 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$80,019

Of which drugs: $11,676

Medicare patients

347

Average age 76

Services billed

6,247

190 women, 157 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 51%
Chronic kidney disease 35%
Ischemic heart disease 31%
Heart failure 27%
Depression 25%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 99 $69
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 21 87 $7

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $97
$97 — —
DALVANCE
  • AbbVie, Inc. $38
$38 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

334 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record